19. The glycoprotein according to any of claims 13-18, which glycoprotein is Itolizumab.
20. The glycoprotein according to any of claims 13-19, which glycoprotein effects an in vitro-or in vivo reduction of cells being positive for CD25 and CD4, in particular of CD4+ T cells.
21. Use of a glycoprotein according to any of claims 13-20 for the manufacture of a medicament for the treatment of a human or animal patient
22. Use of a glycoprotein according to any of claims 13-20, for the treatment of a human or animal patient.
23. Use according to any of claims 21 - 22, wherein the human or animal patient suffers from or has been diagnosed to be at risk to develop, a disease selected from the group consisting of

• Neoplastic diseases, including tumors, lymphomas and leukemias, in particular B-cell chronic Lymphocytic leiikerriia,(BnCLL}..and T-cell leukemia
• Autoimmune disease, including Rheumatoid arthritis, Psoriasis, Crohn's disease, Lupus erythematosus, Sjogren's disease
• Neurodegenerative diseases, including Multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease and/or Amyotrophic lateral sclerosis.
« Infectious diseases
24. Use according to any of claims 21 - 23 in the treatment or prevention of averse reactions like
GVHD (Graft vs. Host disease) in a human or animal that has been transplanted.